Tags : Seizure Cluster

UCB’s Nayzilam (midazolam) Receives FDA’s Approval for the Treatment of

Tuba Khan May 21, 2019

Shots: The approval follows Study 1 consisting of two phases ie, Test Dose Phase & Comparative Phase assessing Nayzilam (midazolam) vs PBO in 292 & 201 patients with intermittent, stereotypic […]readmore

Tags : Seizure Cluster

UCB’s Nayzilam (midazolam) Receives FDA’s Approval for the Treatment of

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Seizure Cluster

﻿UCB’s Nayzilam (midazolam) Receives FDA’s Approval for the Treatment of

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

UCB’s Nayzilam (midazolam) Receives FDA’s Approval for the Treatment of